Thermo Fisher Scientific Inc. (0R0H.L)
USD 447.96
(0.78%)
USD 447.96
(0.78%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.25 Billion USD | -28.08% |
| 2022 | 10.99 Billion USD | 9.83% |
| 2021 | 10 Billion USD | 16.22% |
| 2020 | 8.61 Billion USD | 12.63% |
| 2019 | 7.64 Billion USD | 1.53% |
| 2018 | 7.53 Billion USD | 9.27% |
| 2017 | 6.89 Billion USD | 11.58% |
| 2016 | 6.17 Billion USD | 7.77% |
| 2015 | 5.73 Billion USD | -4.71% |
| 2014 | 6.01 Billion USD | 47.99% |
| 2013 | 4.06 Billion USD | 2.81% |
| 2012 | 3.95 Billion USD | 8.5% |
| 2011 | 3.64 Billion USD | 12.15% |
| 2010 | 3.24 Billion USD | 6.86% |
| 2009 | 3.03 Billion USD | 3.34% |
| 2008 | 2.94 Billion USD | 5.51% |
| 2007 | 2.78 Billion USD | 117.73% |
| 2006 | 1.28 Billion USD | 40.0% |
| 2005 | 914.56 Million USD | 20.16% |
| 2004 | 761.13 Million USD | 6.52% |
| 2003 | 714.53 Million USD | -0.73% |
| 2002 | 719.77 Million USD | -9.09% |
| 2001 | 791.71 Million USD | -3.88% |
| 2000 | 823.67 Million USD | -13.99% |
| 1999 | 957.7 Million USD | -34.73% |
| 1998 | 1.46 Billion USD | 11.68% |
| 1997 | 1.31 Billion USD | 18.79% |
| 1996 | 1.1 Billion USD | 32.38% |
| 1995 | 835.4 Million USD | 54.93% |
| 1994 | 539.2 Million USD | 30.56% |
| 1993 | 413 Million USD | 37.25% |
| 1992 | 300.9 Million USD | 17.08% |
| 1991 | 257 Million USD | 12.03% |
| 1990 | 229.4 Million USD | 29.53% |
| 1989 | 177.1 Million USD | 13.74% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.49 Billion USD | -5.49% |
| 2024 Q3 | 2.57 Billion USD | -3.71% |
| 2024 Q2 | 2.58 Billion USD | 3.56% |
| 2023 Q2 | 2.6 Billion USD | 0.19% |
| 2023 Q3 | 2.48 Billion USD | -4.69% |
| 2023 Q4 | 2.64 Billion USD | 6.49% |
| 2023 FY | 7.9 Billion USD | -28.08% |
| 2023 Q1 | 2.59 Billion USD | -7.84% |
| 2022 Q4 | 2.81 Billion USD | 4.87% |
| 2022 Q1 | 2.78 Billion USD | -1.24% |
| 2022 Q2 | 2.7 Billion USD | -2.73% |
| 2022 FY | 10.99 Billion USD | 9.83% |
| 2022 Q3 | 2.68 Billion USD | -0.63% |
| 2021 FY | 10 Billion USD | 16.22% |
| 2021 Q1 | 2.28 Billion USD | -11.4% |
| 2021 Q2 | 2.4 Billion USD | 5.25% |
| 2021 Q3 | 2.5 Billion USD | 3.95% |
| 2021 Q4 | 2.81 Billion USD | 12.59% |
| 2020 Q1 | 1.92 Billion USD | 1.21% |
| 2020 Q4 | 2.58 Billion USD | 28.17% |
| 2020 Q2 | 2.09 Billion USD | 9.21% |
| 2020 FY | 8.61 Billion USD | 12.63% |
| 2020 Q3 | 2.01 Billion USD | -4.05% |
| 2019 Q1 | 1.9 Billion USD | 0.8% |
| 2019 Q2 | 1.81 Billion USD | -4.73% |
| 2019 Q3 | 1.91 Billion USD | 5.52% |
| 2019 Q4 | 1.89 Billion USD | -0.68% |
| 2019 FY | 7.64 Billion USD | 1.53% |
| 2018 Q1 | 1.87 Billion USD | 2.23% |
| 2018 Q4 | 1.88 Billion USD | 9.02% |
| 2018 FY | 7.53 Billion USD | 9.27% |
| 2018 Q3 | 1.73 Billion USD | -3.03% |
| 2018 Q2 | 1.78 Billion USD | -5.01% |
| 2017 Q3 | 1.74 Billion USD | 6.56% |
| 2017 Q1 | 1.67 Billion USD | 4.12% |
| 2017 Q2 | 1.63 Billion USD | -2.05% |
| 2017 Q4 | 1.83 Billion USD | 5.26% |
| 2017 FY | 6.89 Billion USD | 11.58% |
| 2016 FY | 6.17 Billion USD | 7.77% |
| 2016 Q1 | 1.49 Billion USD | 1.04% |
| 2016 Q3 | 1.56 Billion USD | 3.63% |
| 2016 Q4 | 1.6 Billion USD | 2.42% |
| 2016 Q2 | 1.51 Billion USD | 1.5% |
| 2015 FY | 5.73 Billion USD | -4.71% |
| 2015 Q1 | 1.41 Billion USD | -0.58% |
| 2015 Q2 | 1.43 Billion USD | 1.55% |
| 2015 Q3 | 1.41 Billion USD | -1.4% |
| 2015 Q4 | 1.47 Billion USD | 4.42% |
| 2014 Q4 | 1.41 Billion USD | -6.31% |
| 2014 Q1 | 1.41 Billion USD | 34.11% |
| 2014 Q2 | 1.55 Billion USD | 9.41% |
| 2014 Q3 | 1.51 Billion USD | -2.4% |
| 2014 FY | 6.01 Billion USD | 47.99% |
| 2013 Q2 | 1.02 Billion USD | 3.91% |
| 2013 Q1 | 983.8 Million USD | 3.0% |
| 2013 FY | 4.06 Billion USD | 2.81% |
| 2013 Q4 | 1.05 Billion USD | 5.75% |
| 2013 Q3 | 1 Billion USD | -2.17% |
| 2012 Q3 | 986 Million USD | 0.33% |
| 2012 Q2 | 982.8 Million USD | 0.59% |
| 2012 Q1 | 977 Million USD | -0.51% |
| 2012 FY | 3.95 Billion USD | 8.5% |
| 2012 Q4 | 955.1 Million USD | -3.13% |
| 2011 Q4 | 982 Million USD | 4.03% |
| 2011 Q1 | 816.9 Million USD | 2.61% |
| 2011 Q2 | 900.1 Million USD | 10.18% |
| 2011 Q3 | 944 Million USD | 4.88% |
| 2011 FY | 3.64 Billion USD | 12.15% |
| 2010 FY | 3.24 Billion USD | 6.86% |
| 2010 Q4 | 796.1 Million USD | -0.77% |
| 2010 Q3 | 802.3 Million USD | 0.84% |
| 2010 Q2 | 795.6 Million USD | -2.95% |
| 2010 Q1 | 819.8 Million USD | 3.75% |
| 2009 Q4 | 790.2 Million USD | 4.91% |
| 2009 FY | 3.03 Billion USD | 3.34% |
| 2009 Q2 | 749.2 Million USD | 9.66% |
| 2009 Q3 | 753.2 Million USD | 0.53% |
| 2009 Q1 | 683.2 Million USD | -5.64% |
| 2008 Q4 | 724 Million USD | -0.97% |
| 2008 FY | 2.94 Billion USD | 5.51% |
| 2008 Q1 | 723.1 Million USD | -1.91% |
| 2008 Q2 | 763.3 Million USD | 5.56% |
| 2008 Q3 | 731.1 Million USD | -4.22% |
| 2007 Q1 | 680.1 Million USD | 27.11% |
| 2007 Q4 | 737.2 Million USD | 7.57% |
| 2007 FY | 2.78 Billion USD | 117.73% |
| 2007 Q2 | 685.3 Million USD | 0.76% |
| 2007 Q3 | 685.3 Million USD | 0.0% |
| 2006 FY | 1.28 Billion USD | 40.0% |
| 2006 Q1 | 241.18 Million USD | -3.37% |
| 2006 Q3 | 256.59 Million USD | 3.66% |
| 2006 Q4 | 535.06 Million USD | 108.53% |
| 2006 Q2 | 247.53 Million USD | 2.63% |
| 2005 Q4 | 249.6 Million USD | 7.08% |
| 2005 FY | 914.56 Million USD | 20.16% |
| 2005 Q3 | 233.1 Million USD | 0.43% |
| 2005 Q2 | 232.11 Million USD | 16.16% |
| 2005 Q1 | 199.82 Million USD | -5.25% |
| 2004 Q3 | 186.29 Million USD | 4.02% |
| 2004 Q1 | 203.53 Million USD | 7.77% |
| 2004 FY | 761.13 Million USD | 6.52% |
| 2004 Q4 | 210.91 Million USD | 13.21% |
| 2004 Q2 | 179.1 Million USD | -12.0% |
| 2003 Q2 | 179.99 Million USD | 2.01% |
| 2003 Q3 | 169.24 Million USD | -5.97% |
| 2003 Q4 | 188.85 Million USD | 11.58% |
| 2003 Q1 | 176.44 Million USD | -4.75% |
| 2003 FY | 714.53 Million USD | -0.73% |
| 2002 FY | 719.77 Million USD | -9.09% |
| 2002 Q3 | 176.87 Million USD | -1.25% |
| 2002 Q2 | 179.12 Million USD | 0.33% |
| 2002 Q1 | 178.53 Million USD | -9.23% |
| 2002 Q4 | 185.23 Million USD | 4.72% |
| 2001 Q4 | 196.7 Million USD | 3.38% |
| 2001 FY | 791.71 Million USD | -3.88% |
| 2001 Q3 | 190.28 Million USD | -4.96% |
| 2001 Q2 | 200.2 Million USD | -2.12% |
| 2001 Q1 | 204.53 Million USD | 90.42% |
| 2000 Q4 | 107.41 Million USD | -52.49% |
| 2000 FY | 823.67 Million USD | -13.99% |
| 2000 Q3 | 226.09 Million USD | -7.28% |
| 2000 Q1 | 246.32 Million USD | 178.17% |
| 2000 Q2 | 243.85 Million USD | -1.0% |
| 1999 Q2 | 440.5 Million USD | 8.82% |
| 1999 FY | 957.7 Million USD | -34.73% |
| 1999 Q1 | 404.8 Million USD | 5.42% |
| 1999 Q4 | -315.1 Million USD | -173.72% |
| 1999 Q3 | 427.4 Million USD | -2.97% |
| 1998 FY | 1.46 Billion USD | 11.68% |
| 1998 Q1 | 356.2 Million USD | -2.7% |
| 1998 Q2 | 358.3 Million USD | 0.59% |
| 1998 Q3 | 368.6 Million USD | 2.87% |
| 1998 Q4 | 384 Million USD | 4.18% |
| 1997 FY | 1.31 Billion USD | 18.79% |
| 1997 Q4 | 366.1 Million USD | 13.34% |
| 1997 Q3 | 323 Million USD | 9.6% |
| 1997 Q2 | 294.7 Million USD | 11.71% |
| 1997 Q1 | 263.8 Million USD | -29.47% |
| 1996 FY | 1.1 Billion USD | 32.38% |
| 1996 Q1 | 214.9 Million USD | -26.05% |
| 1996 Q4 | 374 Million USD | 48.0% |
| 1996 Q2 | 255.7 Million USD | 18.99% |
| 1996 Q3 | 252.7 Million USD | -1.17% |
| 1995 Q2 | 184.6 Million USD | 6.89% |
| 1995 Q4 | 290.6 Million USD | 54.99% |
| 1995 Q3 | 187.5 Million USD | 1.57% |
| 1995 Q1 | 172.7 Million USD | -9.15% |
| 1995 FY | 835.4 Million USD | 54.93% |
| 1994 Q2 | 119.3 Million USD | 13.08% |
| 1994 Q3 | 124.3 Million USD | 4.19% |
| 1994 Q4 | 190.1 Million USD | 52.94% |
| 1994 FY | 539.2 Million USD | 30.56% |
| 1994 Q1 | 105.5 Million USD | -26.48% |
| 1993 Q2 | 91.6 Million USD | -8.31% |
| 1993 Q4 | 143.5 Million USD | 58.91% |
| 1993 Q1 | 99.9 Million USD | -13.88% |
| 1993 Q3 | 90.3 Million USD | -1.42% |
| 1993 FY | 413 Million USD | 37.25% |
| 1992 Q3 | 68.6 Million USD | 17.26% |
| 1992 Q4 | 116 Million USD | 69.1% |
| 1992 Q1 | 57.8 Million USD | -29.08% |
| 1992 Q2 | 58.5 Million USD | 1.21% |
| 1992 FY | 300.9 Million USD | 17.08% |
| 1991 Q3 | 57.5 Million USD | -0.52% |
| 1991 Q4 | 81.5 Million USD | 41.74% |
| 1991 Q1 | 56.6 Million USD | -26.49% |
| 1991 FY | 257 Million USD | 12.03% |
| 1991 Q2 | 57.8 Million USD | 2.12% |
| 1990 Q3 | 56 Million USD | -4.44% |
| 1990 Q4 | 77 Million USD | 37.5% |
| 1990 Q1 | 43.3 Million USD | -14.26% |
| 1990 Q2 | 58.6 Million USD | 35.33% |
| 1990 FY | 229.4 Million USD | 29.53% |
| 1989 Q1 | - USD | 100.0% |
| 1989 FY | 177.1 Million USD | 13.74% |
| 1989 Q4 | 50.5 Million USD | 16.9% |
| 1989 Q2 | - USD | 0.0% |
| 1989 Q3 | 43.2 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | -3496.809% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -3619.354% |
| bluebird bio, Inc. | 240.23 Million USD | -4168.374% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -7097.658% |
| Editas Medicine, Inc. | 247.3 Million USD | -4046.314% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -399.464% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -841.261% |
| Myriad Genetics, Inc. | 600.1 Million USD | -1608.715% |
| Biogen Inc. | 5.2 Billion USD | -97.007% |
| Nektar Therapeutics | 190.9 Million USD | -5271.314% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -2408.28% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -2297.75% |
| Imunon, Inc. | 21.03 Million USD | -48657.919% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -542.28% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -1838.334% |
| Verastem, Inc. | 92.08 Million USD | -11035.485% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 74.744% |
| Waters Corporation | 943.51 Million USD | -986.785% |
| Perrigo Company plc | 1.52 Billion USD | -570.854% |
| Dynavax Technologies Corporation | 219.14 Million USD | -4579.094% |
| Illumina, Inc. | 3.81 Billion USD | -168.922% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -73618.653% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -2173.649% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -8398.471% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -22856.545% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -487.193% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -4383.995% |
| Evolus, Inc. | 189.75 Million USD | -5303.696% |
| Adicet Bio, Inc. | 152.03 Million USD | -6644.367% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -84357.623% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -264.224% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -3671.281% |
| FibroGen, Inc. | 398.11 Million USD | -2475.651% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -384.823% |
| OPKO Health, Inc. | 574.68 Million USD | -1684.279% |
| Homology Medicines, Inc. | 9.87 Million USD | -103737.975% |
| Geron Corporation | 70.44 Million USD | -14456.863% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -469.647% |
| Exelixis, Inc. | 1.58 Billion USD | -546.216% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -10069.895% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -18290.846% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -1759.07% |
| Zoetis Inc. | 2.76 Billion USD | -270.85% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -2052.574% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -21041.396% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | -114.743% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -26089.564% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -1215.312% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -653.518% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -2681.787% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -3325.788% |
| Blueprint Medicines Corporation | 722.86 Million USD | -1318.53% |
| Insmed Incorporated | 949.26 Million USD | -980.209% |
| TG Therapeutics, Inc. | 198.47 Million USD | -5066.394% |
| Incyte Corporation | 1.19 Billion USD | -761.322% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -882.184% |